ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis

Cellular Oncology

Volumn 28, Issue 5-6, 2006, Pages 259-272

  Lind, Guro E ^a   Kleivi, Kristine ^a,e   Meling, Gunn I ^b   Teixeira, Manuel R ^c   Thiis Evensen, Espen ^a   Rognum, Torleiv O ^a   Lothe, Ragnhild A ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d UNIVERSITY OF OSLO   (Norway)

^e VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

5 aza 2 deoxycytidine; ADAMTS1; Adenomas; Bisulphite sequencing; Colorectal carcinomas; CRABP1; Gene expression; Methylation; Microarrays; NR3C1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; GENE PRODUCT; PROTEIN ADAMTS1; PROTEIN CRABP1; PROTEIN NR3C1;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SEQUENCE; GENE TARGETING; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY; MAJOR CLINICAL STUDY; MALE; METHYLATION; MICROARRAY ANALYSIS; OBSERVATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; QUANTITATIVE GENETICS; TESTIS;

ADAM PROTEINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MICROARRAY ANALYSIS; PROMOTER REGIONS (GENETICS); RECEPTORS, GLUCOCORTICOID; RECEPTORS, RETINOIC ACID; SEQUENCE ANALYSIS, DNA; TUMOR CELLS, CULTURED;

EID: 33845679095     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. L.A. Aaltonen, P. Peltomäki, F.S. Leach, P. Sistonen, L. Pylkkänen, J.P. Mecklin, H. Järvinen, S.M. Powell, J. Jen, S.R. Hamilton, G.M. Petersen, K.W. Kinzler, B. Vogelstein and A. de la Chapelle, Clues to the pathogenesis of familial colorectal cancer, Science 260 (1993), 812-816.
2. A.A. Alizadeh, M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, A. Rosenwald, J.C. Boldrick, H. Sabet, T. Tran, X. Yu, J.I. Powell, L. Yang, G.E. Marti, T. Moore, J. Hudson, Jr., et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403 (2000), 503-511.
3. C. Anacleto, A.M. Leopoldino, B. Rossi, F.A. Soares, A. Lopes, J.C. Rocha, O. Caballero, A.A. Camargo, A.J. Simpson and S.D. Pena, Colorectal cancer "methylator phenotype": fact or artifact?, Neoplasia 7 (2005), 331-335.
4. S.S. Apte, A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family, Int. J. Biochem. Cell Biol. 36 (2004), 981-985.
5. A. Åstrøm, A. Tavakkol, U. Pettersson, M. Cromie, J.T. Elder and J.J. Voorhees, Molecular cloning of two human cellular retinoic acid-binding proteins (CRABP). Retinoic acid induced expression of CRABP-II but not CRABP-I in adult human skin in vivo and in skin fibroblasts in vitro, J. Biol. Chem. 266 (1991), 17662-17666.
6. A.L. Børresen-Dale, R.A. Lothe, G.I. Meling, P. Hainaut, T.O. Rognum and E. Skovlund, TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival, Clin. Cancer Res. 4 (1998), 203-210.
7. P.J. Bray and R.G. Cotton, Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms, Hum. Mutat. 21 (2003), 557-568.
8. S.J. Clark, J. Harrison, C.L. Paul and M. Frommer, High sensitivity mapping of methylated cytosines, Nucleic. Acids. Res. 22 (1994), 2990-2997.
9. A. de la Chapelle, Genetic predisposition to colorectal cancer, Nat. Rev. Cancer 4 (2004), 769-780.
10. S. Derks, M.H. Lentjes, D.M. Hellebrekers, A.P. de Bruine, J.G. Herman and M. van Engeland, Methylation-specific PCR unraveled, Cell Oncol. 26 (2004), 291-299.
11. M.F. Fraga and M. Esteller, DNA methylation: a profile of methods and applications, Biotechniques 33 (2002), 632-649.
12. Y. Funakoshi, H. Shiono, M. Inoue, Y. Kadota, M. Ohta, H. Matsuda, M. Okumura and T. Eimoto, Glucocorticoids induce G1 cell cycle arrest in human neoplastic thymic epithelial cells, J. Cancer Res. Clin. Oncol. 131 (2005), 314-322.
13. P.S. Gaynon and A.L. Carrel, Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia, Adv. Exp. Med. Biol. 457 (1999), 593-605.
14. U.E. Gibson, C.A. Heid and P.M. Williams, A novel method for real time quantitative RT-PCR, Genome Res. 6 (1996), 995-1001.
15. A.K. Greenberg, J. Hu, S. Basu, J. Hay, J. Reibman, T.A. Yie, K.M. Tchou-Wong, W.N. Rom and T.C. Lee, Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators, Am. J. Respir. Cell Mol. Biol. 27 (2002), 320-328.
16. C. Grunau, S.J. Clark and A. Rosenthal, Bisulfite genomic sequencing: systematic investigation of critical experimental parameters, Nucleic Acids Res. 29 (2001), E65.
17. R.J. Guan, H.L. Ford, Y. Fu, Y. Li, L.M. Shaw and A.B. Pardee, Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer, Cancer Res. 60 (2000), 749-755.
18. C.A. Heid, J. Stevens, K.J. Livak and P.M. Williams, Real time quantitative PCR, Genome Res. 6 (1996), 986-994.
19. J.G. Herman, J.R. Graff, S. Myöhänen, B.D. Nelkin and S.B. Baylin, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands, Proc. Natl. Acad. Sci. U.S.A. 93 (1996), 9821-9826.
20. J.G. Herman, A. Umar, K. Polyak, J.R. Graff, N. Ahuja, J.P. Issa, S. Markowitz, J.K. Willson, S.R. Hamilton, K.W. Kinzler, M.F. Kane, R.D. Kolodner, B. Vogelstein, T.A. Kunkel and S.B. Baylin, Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma, Proc. Natl. Acad. Sci. U.S.A. 95 (1998), 6870-6875.
21. Y. Huang, C.A. de la Chapelle and N.S. Pellegata, Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma, Int. J. Cancer 104 (2003), 735-744.
22. P.A. Jones and S.B. Baylin, The fundamental role of epigenetic events in cancer, Nat. Rev. Genet. 3 (2002), 415-428.
23. K. Kleivi, M.R. Teixeira, M. Eknaes, C.B. Diep, K.S. Jakobsen, R. Hamelin and R.A. Lothe, Genome signatures of colon carcinoma cell lines, Cancer Genet. Cytogenet. 155 (2004), 119-131.
24. K. Kuno, K. Bannai, M. Hakozaki, K. Matsushima and K. Hirose, The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential, Biochem. Biophys. Res. Commun. 319 (2004), 1327-1333.
25. K. Kuno, N. Kanada, E. Nakashima, F. Fujiki, F. Ichimura and K. Matsushima, Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene, J. Biol. Chem. 272 (1997), 556-562.
26. S. Lee, K.S. Hwang, H.J. Lee, J.S. Kim and G.H. Kang, Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia, Lab. Invest. 84 (2004), 884-893.
27. L.C. Li and R. Dahiya, MethPrimer: designing primers for methylation PCRs, Bioinformatics 18 (2002), 1427-1431.
28. G. Liang, F.A. Gonzales, P.A. Jones, T.F. Orntoft and T. Thykjaer, Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine, Cancer Res. 62 (2002), 961-966.
29. G.E. Lind, L. Thorstensen, T. Løvig, G.I. Meling, R. Hamelin, T.O. Rognum, M. Esteller and R.A. Lothe, A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines, Mol. Cancer 3 (2004), 28.
30. D. Lodygin, A. Epanchintsev, A. Menssen, J. Diebold and H. Hermeking, Functional epigenomics identifies genes frequently silenced in prostate cancer, Cancer Res. 65 (2005), 4218-4227.
31. R.A. Lothe, P. Peltomäki, G.I. Meling, L.A. Aaltonen, M. Nyström-Lahti, L. Pylkkänen, K. Heimdal, T.I. Andersen, P. Møller, T.O. Rognum, S.D. Fosså, T. Haldorsen, F. Langmark, A. Brøgger, A. de la Chapelle and A.L. Børresen, Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history, Cancer Res. 53 (1993), 5849-5852.
32. A. Luque, D.R. Carpizo and M.L. Iruela-Arispe, ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165, J. Biol. Chem. 278 (2003), 23656-23665.
33. T. Masui, R. Hosotani, S. Tsuji, Y. Miyamoto, S. Yasuda, J. Ida, S. Nakajima, M. Kawaguchi, H. Kobayashi, M. Koizumi, E. Toyoda, S. Tulachan, S. Arii, R. Doi and M. Imamura, Expression of METH-1 and METH-2 in pancreatic cancer, Clin. Cancer Res. 7 (2001), 3437-3443.
34. G.I. Meling, R.A. Lothe, A.L. Børresen, S. Hauge, C. Graue, O.P. Clausen and T.O. Rognum, Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis, Br. J. Cancer 64 (1991), 475-480.
35. J.R. Melki, P.C. Vincent and S.J. Clark, Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia, Cancer Res. 59 (1999), 3730-3740.
36. Y. Mori, K. Cai, Y. Cheng, S. Wang, B. Paun, J.P. Hamilton, Z. Jin, F. Sato, A.T. Berki, T. Kan, T. Ito, C. Mantzur, J.M. Abraham and S.J. Meltzer, A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer, Gastroenterology 131 (2006), 797-808.
37. Y. Mori, J. Yin, F. Sato, A. Sterian, L.A. Simms, F.M. Selaru, K. Schulmann, Y. Xu, A. Olaru, S. Wang, E. Deacu, J.M. Abraham, J. Young, B.A. Leggett and S.J. Meltzer, Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning, Cancer Res. 64 (2004), 2434-2438.
38. R.M. Niles, Signaling pathways in retinoid chemoprevention and treatment of cancer, Mutat. Res. 555 (2004), 81-96.
39. S. Ogino, M. Cantor, T. Kawasaki, M. Brahmandam, G. Kirkner, D.J. Weisenberger, M. Campan, P.W. Laird, M. Loda and C.S. Fuchs, CpG island methylator phenotype (CIMP) of colorectal cancer is best characterized by quantitative DNA methylation analysis and prospective cohort studies, Gut 55 (2006), 1000-1006.
40. S. Porter, I.M. Clark, L. Kevorkian and D.R. Edwards, The ADAMTS metalloproteinases, Biochem. J. 386 (2005), 15-27.
41. S. Porter, S.D. Scott, E.M. Sassoon, M.R. Williams, J.L. Jones, A.C. Girling, R.Y. Ball and D.R. Edwards, Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma, Clin. Cancer Res. 10 (2004), 2429-2440.
42. H. Rajagopalan, M.A. Nowak, B. Vogelstein and C. Lengauer, The significance of unstable chromosomes in colorectal cancer, Nat. Rev. Cancer 3 (2003), 695-701.
43. K. Rand, W. Qu, T. Ho, S.J. Clark and P. Molloy, Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives, Methods 27 (2002), 114-120.
44. A. Rashid, L. Shen, J.S. Morris, J.P. Issa and S.R. Hamilton, CpG island methylation in colorectal adenomas, Am. J. Pathol. 159 (2001), 1129-1135.
45. M. van Rijnsoever, F. Grieu, H. Elsaleh, D. Joseph and B. Iacopetta, Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands, Gut 51 (2002), 797-802.
46. L.H. Saal, C. Troein, J. Vallon-Christersson, S. Gruvberger, A. Borg and C. Peterson, BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data, Genome Biol. 3 (2002), SOFTWARE0003.
47. W.S. Samowitz, H. Albertsen, J. Herrick, T.R. Levin, C. Sweeney, M.A. Murtaugh, R.K. Wolff and M.L. Slattery, Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer, Gastroenterology 129 (2005), 837-845.
48. S. Schmidt, J. Rainer, C. Ploner, E. Presul, S. Riml and R. Kofler, Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance, Cell Death. Differ. 11 Suppl 1 (2004), S45-S55.
49. S. Sengupta and B. Wasylyk, Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors, Ann. N. Y. Acad. Sci. 1024 (2004), 54-71.
50. D.J. Smiraglia, L.J. Rush, M.C. Fruhwald, Z. Dai, W.A. Held, J.F. Costello, J.C. Lang, C. Eng, B. Li, F.A. Wright, M.A. Caligiuri and C. Plass, Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies, Hum. Mol. Genet. 10 (2001), 1413-1419.
51. B. Smith-Sørensen, G.E. Lind, R.I. Skotheim, S.D. Fosså, Ø. Fodstad, A.E. Stenwig, K.S. Jakobsen and R.A. Lothe, Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer, Oncogene 21 (2002), 8878-8884.
52. H. Suzuki, E. Gabrielson, W. Chen, R. Anbazhagan, M. van Engeland, M.P. Weijenberg, J.G. Herman and S.B. Baylin, A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer, Nat. Genet. 31 (2002), 141-149.
53. D. Takai and P.A. Jones, Comprehensive analysis of CpG islands in human chromosomes 21 and 22, Proc. Natl. Acad. Sci. U.S.A. 99 (2002), 3740-3745.
54. S. Theocharis, G. Kouraklis, A. Margeli, E. Agapitos, S. Ninos, G. Karatzas and A. Koutselinis, Glucocorticoid receptor (GR) immunohistochemical expression is correlated with cell cycle-related molecules in human colon cancer, Dig. Dis. Sci. 48 (2003), 1745-1750.
55. E. Thiis-Evensen, G.S. Hoff, J. Sauar, F. Langmark, B.M. Majak and M.H. Vatn, Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I, Scand. J. Gastroenterol. 34 (1999), 414-420.
56. M. Toyota, N. Ahuja, M. Ohe-Toyota, J.G. Herman, S.B. Baylin and J.P. Issa, CpG island methylator phenotype in colorectal cancer, Proc. Natl. Acad. Sci. U.S.A. 96 (1999), 8681-8686.
57. M. Toyota and J.P. Issa, CpG island methylator phenotypes in aging and cancer, Semin. Cancer Biol. 9 (1999), 349-357.
58. L.N. Wei and C.H. Lee, Demethylation in the 5′-flanking region of mouse cellular retinoic acid binding protein-I gene is associated with its high level of expression in mouse embryos and facilitates its induction by retinoic acid in P19 embryonal carcinoma cells, Dev. Dyn. 201 (1994), 1-10.
59. D.J. Weisenberger, K.D. Siegmund, M. Campan, J. Young, T.I. Long, M.A. Faasse, G.H. Kang, M. Widschwendter, D. Weener, D. Buchanan, H. Koh, L. Simms, M. Barker, B. Leggett, J. Levine, M. Kim, A.J. French, S.N. Thibodeau, J. Jass, R. Haile and P.W. Laird, CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, Nat. Genet. 38 (2006), 787-793.
60. V.L. Whitehall, C.V. Wynter, M.D. Walsh, L.A. Simms, D. Purdie, N. Pandeya, J. Young, S.J. Meltzer, B.A. Leggett and J.R. Jass, Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer, Cancer Res. 62 (2002), 6011-6014.
61. K. Yamashita, T. Dai, Y. Dai, F. Yamamoto and M. Perucho, Genetics supersedes epigenetics in colon cancer phenotype, Cancer Cell 4 (2003), 121-131.
62. Y.H. Yang, S. Dudoit, P. Luu, D.M. Lin, V. Peng, J. Ngai and T.P. Speed, Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation, Nucleic Acids Res. 30 (2002), e15.